Regeneron, Sanofi-Aventis Initiate Oncology Program for Aflibercept

Regeneron Pharmaceuticals and sanofi-aventis announced the initiation of two Phase III trials evaluating the safety and efficacy of aflibercept in combination with standard chemotherapy regimens in patients with prostate cancer and non-small cell lung cancer.

Aflibercept (VEGF Trap) is an anti-angiogenic agent targeting vascular endothelial growth factor (VEGF). These two trials will be double-blind and placebo-controlled. 

Sanofi-aventis said it will provide an update of the clinical development program planned for aflibercept Sept. 17.